Eli Lilly Continues Neuroscience Expansion with US$1.36 B Disarm Therapeutics Buy
By Neha Madhwani & Michelle Liu
Pharma Deals Review: Vol 2020 Issue 12 (Table of Contents)
Published: 9 Dec-2020
DOI: 10.3833/pdr.v2020.i12.2575 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Eli Lilly has agreed to acquire axonal degeneration specialist Disarm Therapeutics in exchange for US$135 M upfront...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS